Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Calendar quarter Q2 2026Earnings call Jul 24, 2026 · most recent call
HCA’s newest analyzed quarter is part of Tellvest Pro: its score, breakdown, narrative and analyst Q&A. Every prior quarter is free.
Sources. Scores: HCA Healthcare’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: HCA daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
All prior quarters are free. How to browse earnings-call scores without Pro. How to read a company earnings-call score.
Reporting soon: earnings call Tuesday, Oct 27
A pre-earnings brief is ready for HCA: the setup, what peers and partners said this season, and which analysts to watch.Reading it is a Tellvest Pro feature.
The breakdown for this quarter is part of Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
No 8-K events recorded since this call day.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Net margin | FCF |
|---|---|---|---|---|---|---|
| FY2024 Q4 | $18.29B | +5.7% | $5.63 | -5.1% | 7.9% | $1.27B |
| FY2025 Q1 | $18.32B | +5.7% | $6.45 | +8.8% | 8.8% | $660M |
| FY2025 Q2 | $18.61B | +6.4% | $6.83 | +23.5% | 8.9% | $3.03B |
| FY2025 Q3 | $19.16B | +9.6% | $6.96 | +42.6% | 8.6% | $3.13B |
| FY2025 Q4 | $19.51B | +6.7% | $8.14 | +44.6% | 9.6% | $870M |
| FY2026 Q1 | $19.11B | +4.3% | $7.15 | +10.9% | 8.5% | $895M |
| FY2026 Q2Selected | $20.23B | +8.7% | $7.62 | +11.6% | 8.4% | $1.10B |
Management-stated figures from HCA’s newest call are part of Tellvest Pro.